Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of GS-9620 in Virally-Suppressed Chronic Hepatitis B
2014-001400-22Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing GS-9620 with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Jul 2014; status: completed.
02
Drugs
vesatolimod
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2014-001400-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001400-22.